Table of Contents
- Trial overview
- Who can participate
- What is being measured
- Trial phase and design
- Study population and vaccines used
- Why these trials matter
Trial overview
This clinical study is a Phase 3 interventional trial that examines immunity after revaccination in children and adolescents treated for childhood cancer.[1] The trial is authorised and plans to enroll 160 participants.[1]
The study title says it examines cellular and humoral immunity against measles and chickenpox, meaning it looks at both immune cells and antibodies.[1]
Who can participate
The target population is children and adolescents from 0 to 18 years of age with pediatric cancer.[1] The trial is focused on people after treatment for childhood cancer, when doctors want to check whether vaccine protection is present again.[1]
This means the study is not for the general population; it is designed for young patients who have already been treated for cancer.[1]
What is being measured
The main endpoint is the difference in VZ IgG antibody levels before and after revaccination against chickenpox.[1] IgG is a blood antibody that shows how the immune system responds to vaccination.[1]
The study also measures the difference in measles IgG antibody levels before and after revaccination against measles.[1] The brief summary states that the researchers want to compare the proportion of patients with a protective antibody level before and after vaccination.[1]
These outcomes help show whether revaccination improves immune protection after cancer treatment.[1]
Trial phase and design
This is an interventional study, which means the researchers give vaccines and then measure the results.[1] It is listed as Phase 3, so it is studying the vaccine response in a larger group rather than only a small early group.[1]
The interventions listed in the source include measles, mumps, and rubella live attenuated vaccine and varicella live attenuated vaccine, both given as 0.5 ml intramuscular injections.[1] The trial data specifically focus on immune response after these revaccinations.[1]
Study population and vaccines used
The study population includes young people recovering from childhood cancer treatment, a group that may need checks on whether prior vaccine protection is still present.[1] The source also notes both cellular immunity and humoral immunity, which are two parts of the immune system that help defend against infection.[1]
In simple terms, the researchers are asking whether these children and adolescents can build or regain measurable protection against chickenpox and measles after revaccination.[1]
Why these trials matter
Children and adolescents treated for cancer can have changes in their immune response, so studies like this help check whether revaccination leads to protective antibody levels.[1] The trial is important because it uses blood tests before and after vaccination to see if immunity improves.[1]
By measuring antibody changes, the study can show whether revaccination against chickenpox and measles is working as expected in this patient group.[1]
